ARCT Arcturus Therapeutics, Inc.

NASDAQ
$13.85

Arcturus Therapeutics, Inc. (ARCT) is expected to report earnings on November 10, 2026, after the market close. The consensus earnings estimate is a loss of $0.60 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +114.1% since its last earnings release on August 6, 2026.

Arcturus Therapeutics Beat Consensus Estimates
Thursday, August 6, 2026 · 4:01 PM ET
Earnings Date
3rd Quarter, Sep 2026
Nov 10
Tuesday · 4:00 PM ET
Earnings Whisper
-
vs ($0.60)
Rev est $8.47M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $13.29

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Arcturus Therapeutics, Inc.

Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA.

Sector

Healthcare

Industry

Biotechnology

Held By 3 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.